NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Open in Screener

VERA

Vera Therapeutics Inc

Jun 26 • 09:34AM ET

24.18

Dollar change +0.87
Percentage change 3.73	%

Healthcare • Biotechnology • USA • NASD

Peers: ARVN INCY ITCI ALXO BCRX RIGL LGND KURA CRVS AVIR

| Held by: VTI IWM XBI VXF IWO IBB SCHA VTWO VHT LABU

Index	RUT	P/E	-	EPS (ttm)	-3.00	Insider Own	28.06%	Shs Outstand	63.77M	Perf Week	15.58%
Market Cap	1.54B	Forward P/E	-	EPS next Y	-3.42	Insider Trans	1.20%	Shs Float	45.88M	Perf Month	26.99%
Enterprise Value	1.01B	PEG	-	EPS next Q	-0.82	Inst Own	90.09%	Short Float	20.84%	Perf Quarter	-6.68%
Income	-175.46M	P/S	-	EPS this Y	-19.07%	Inst Trans	2.94%	Short Ratio	5.46	Perf Half Y	-43.24%
Sales	0.00M	P/B	2.88	EPS next Y	-4.53%	ROA	-34.09%	Short Interest	9.56M	Perf YTD	-42.82%
Book/sh	8.39	P/C	2.61	EPS next 5Y	10.74%	ROE	-39.49%	52W High	51.61 -53.15%	Perf Year	-30.70%
Cash/sh	9.25	P/FCF	-	EPS past 3/5Y	-21.52% 4.49%	ROIC	-29.83%	52W Low	18.53 30.49%	Perf 3Y	68.50%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.40% 6.70%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-46.70%	Oper. Margin	-	ATR (14)	1.84	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	27.30	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	54.66	Recom	1.14
Dividend Gr. 3/5Y	- -	Current Ratio	27.30	EPS Q/Q	-45.82%	SMA20	1.70%	Beta	1.16	Target Price	63.36
Payout	-	Debt/Eq	0.10	Sales Q/Q	-	SMA50	6.75%	Rel Volume	2.51	Prev Close	23.31
Employees	112	LT Debt/Eq	0.10	Earnings	May 06 BMO	SMA200	-28.59%	Avg Volume	1.75M	Price	24.18
IPO	May 14, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-9.27% -	Trades		Volume	262,852	Change	3.73%

Date	Action	Analyst	Rating Change	Price Target Change
May-05-25	Resumed	H.C. Wainwright	Buy	$75
Feb-04-25	Initiated	Wolfe Research	Outperform	$49
Jan-28-25	Initiated	Goldman	Buy	$58
Nov-21-24	Initiated	Wells Fargo	Overweight	$70
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jan-25-24	Initiated	Oppenheimer	Outperform	$26
Jan-08-24	Initiated	Cantor Fitzgerald	Overweight
Dec-18-23	Initiated	Raymond James	Outperform	$29
Nov-10-23	Upgrade	Jefferies	Hold → Buy	$18 → $26
Aug-16-23	Initiated	Guggenheim	Buy	$27
Jan-04-23	Downgrade	Wedbush	Outperform → Neutral	$33 → $8
Jan-04-23	Downgrade	Jefferies	Buy → Hold	$32 → $6
Jul-12-22	Initiated	JP Morgan	Overweight	$35
May-02-22	Initiated	H.C. Wainwright	Buy	$35
Apr-19-22	Initiated	Wedbush	Outperform	$32

Show Previous Ratings

Jun-12-25 01:57PM	Analysts Can't Get Enough of These Little-Known Biopharma Stocks (MarketBeat)
Jun-09-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-06-25 11:02AM	Biotech Stock Vera Is Slumping After Monster Gain (Barrons.com) -25.89%
07:49AM	Vera Therapeutics stock sinks following competitors successful trial (Investing.com)
Jun-04-25 04:05PM	Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
06:30AM	Loading…
Jun-03-25 06:30AM	Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans (GlobeNewswire)
02:22AM	Why Vera Therapeutics, Inc. (VERA) Skyrocketed On Monday (Insider Monkey)
Jun-02-25 06:30AM	Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy (GlobeNewswire) +67.49%
04:51AM	Vera drug scores in closely watched study in rare kidney disease (BioPharma Dive)
May-09-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-06-25 08:00AM	Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results (GlobeNewswire) -13.79%
Apr-09-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +16.76%
02:51PM	Kidney Disease-Focused Vera Therapeutics Concludes Enrollment In Pivotal Study, Targets 2026 Commercial Launch (Benzinga)
Apr-03-25 08:00AM	Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN (GlobeNewswire)
Mar-11-25 04:28PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Loading…
Feb-27-25 08:00AM	Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference (GlobeNewswire) +5.91%
Feb-26-25 08:25AM	Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-13-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -19.66%
Jan-14-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-13-25 07:00AM	Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor (GlobeNewswire) -6.08%
Jan-07-25 04:05PM	Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-09-24 06:29PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-22-24 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-18-24 08:00AM	Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer (GlobeNewswire)
Nov-11-24 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:55AM	Wall Street Analysts Think Vera Therapeutics (VERA) Could Surge 27.26%: Read This Before Placing a Bet (Zacks)
08:00AM	Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study (GlobeNewswire)
Nov-08-24 04:05PM	Vera Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire)
Nov-07-24 08:00AM	Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-29-24 08:21PM	Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock (GlobeNewswire) -9.23% -5.42%
09:25AM	Loading…
09:25AM	Vera Therapeutics price target raised to $64 from $56 at Guggenheim (TipRanks)
Oct-28-24 05:43PM	Vera Therapeutics Breaks Out On Promising Results For Kidney Drug (Investor's Business Daily) +15.21%
05:37PM	Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock (GlobeNewswire)
10:33AM	Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years (Benzinga)
10:13AM	Vera Therapeutics Eyes Breakout On Promising Results For Kidney Drug (Investor's Business Daily)
Oct-26-24 07:30PM	Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 (GlobeNewswire)
Oct-04-24 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-02-24 06:30AM	Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024 (GlobeNewswire)
06:30AM	Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases (GlobeNewswire)
Sep-26-24 03:31PM	Is Vera Therapeutics Inc. (VERA) the Best Performing Small-Cap Stock in 2024? (Insider Monkey)
Sep-16-24 08:00AM	Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024 (GlobeNewswire) +6.90%
Sep-12-24 08:00AM	Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN (GlobeNewswire) -5.08%
Sep-10-24 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-05-24 01:07AM	Vera Therapeutics, Inc. (VERA): Among the Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Sep-03-24 08:27AM	Adobe Stock Added to JP Morgan Focus List. Heres Why. (Barrons.com)
08:27AM	Adobe and 2 More Stocks Added to JP Morgan Focus List. Heres Why. (Barrons.com)
07:49AM	Load Up on Adobe and These 2 Stocks This September, J.P. Morgan Says (Barrons.com)
Sep-02-24 06:05PM	10 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-29-24 08:00AM	Vera Therapeutics to Participate at September Investor Conferences (GlobeNewswire)
Aug-09-24 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-08-24 08:00AM	Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-05-24 04:30PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-01-24 08:00AM	Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer (GlobeNewswire)
Jun-11-24 04:01PM	Vera Therapeutics Appoints Christy J. Oliger to Board of Directors (GlobeNewswire)
Jun-07-24 04:05PM	Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-28-24 08:00AM	Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN) (GlobeNewswire)
May-25-24 09:40AM	Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress (GlobeNewswire)
May-17-24 04:27PM	Vera Therapeutics Insider Sold Shares Worth $1,304,435, According to a Recent SEC Filing (MT Newswires)
May-10-24 05:38AM	Wedbush Adjusts Vera Therapeutics' PT to $32 From $34, Keeps Neutral Rating (MT Newswires)
May-09-24 01:53PM	VERA Stock Earnings: Vera Therapeutics Misses EPS for Q1 2024 (InvestorPlace) -5.81%
08:00AM	Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-07-24 04:38PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-23-24 05:09PM	Health Care Roundup: Market Talk (The Wall Street Journal)
Apr-13-24 05:29AM	Could This Stock Be the Next Biotech Buyout? (Motley Fool)
Apr-12-24 07:01PM	Insider Sells at Vera Therapeutics Inc: SVP, Finance, Chief Accounting Officer Joseph Young ... (GuruFocus.com)
Apr-11-24 04:29PM	Vertex Pharmaceuticals to buy Alpine Immune Sciences in $4.9B deal (Yahoo Finance Video) +17.30%
Apr-05-24 06:30PM	ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors (Barrons.com)
Apr-02-24 08:00AM	Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress (GlobeNewswire)
Mar-20-24 12:52PM	VERA Stock Earnings: Vera Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
07:30AM	Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-28-24 04:20PM	Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference (GlobeNewswire)
Feb-02-24 12:40PM	Hedge Fund and Insider Trading News: Anthony Scaramucci, Ray Dalio, Ken Griffin, NWQ Capital Management, Man Group, Cleveland-Cliffs Inc (CLF), Vera Therapeutics, Inc. (VERA), and More (Insider Monkey)
08:00AM	Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Feb-01-24 04:05PM	Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares in Public Offering of Class A Common Stock (GlobeNewswire)
Jan-29-24 11:50PM	Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock (GlobeNewswire) +11.46%
06:15AM	Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock (GlobeNewswire)
Jan-25-24 06:30AM	Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy (GlobeNewswire) +48.71%
Jan-12-24 06:44PM	Why Vera Therapeutics Stock Soared by 22% This Week (Motley Fool) -11.35%
Jan-08-24 08:01AM	Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer (GlobeNewswire) +16.74%
08:00AM	Vera Therapeutics to Host In-Person R&D Day in New York to Present Week 72 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN on January 25, 2024 (GlobeNewswire)
Dec-27-23 08:00AM	Vera Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-15-23 10:15AM	This Promising Small-Cap Biotech Stock Could Rise 70%, According to Wall Street (Motley Fool) +8.70%
Nov-14-23 05:05PM	FMR LLC Adjusts Stake in Vera Therapeutics Inc (GuruFocus.com) +6.74%
09:55AM	Wall Street Analysts Believe Vera Therapeutics, Inc. (VERA) Could Rally 86.76%: Here's is How to Trade (Zacks)
Nov-09-23 09:29AM	Vera Therapeutics Inc (VERA) Reports Q3 Financial Results and Business Updates (GuruFocus.com)
08:00AM	Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results (GlobeNewswire)
Nov-04-23 10:00AM	Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023 (GlobeNewswire)
Oct-30-23 08:00AM	Vera Therapeutics Scheduled to Present at November Investor Conferences (GlobeNewswire) +8.32%
Oct-18-23 09:35AM	Down -34.74% in 4 Weeks, Here's Why You Should You Buy the Dip in Vera Therapeutics, Inc. (VERA) (Zacks) -5.09%
Oct-17-23 09:35AM	Down -38.05% in 4 Weeks, Here's Why You Should You Buy the Dip in Vera Therapeutics, Inc. (VERA) (Zacks)
Oct-16-23 09:35AM	Down -37.74% in 4 Weeks, Here's Why Vera Therapeutics, Inc. (VERA) Looks Ripe for a Turnaround (Zacks)
Oct-13-23 10:22AM	Vera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual Meeting (GlobeNewswire)
Sep-26-23 04:02PM	Why Shares of Vera Therapeutics Jumped Tuesday (Motley Fool) +11.32%
Aug-31-23 08:00AM	Vera Therapeutics Scheduled to Present at September Investor Conferences (GlobeNewswire) -5.70%
Aug-16-23 10:00AM	Chevron upgraded, SolarEdge downgraded: Wall Street's top analyst calls (The Fly)
Aug-15-23 04:03PM	What Makes Vera Therapeutics, Inc. (VERA) a New Buy Stock (Zacks)
Aug-10-23 08:00AM	Vera Therapeutics Provides Business Update and Reports Second Quarter Financial Results (GlobeNewswire) +6.22%
Aug-04-23 06:30PM	Apogee Therapeutics, Turnstone Biologics, and More Stocks See Action From Activist Investors (Barrons.com)
Jul-24-23 09:01AM	Positive Signs As Multiple Insiders Buy Vera Therapeutics Stock (Simply Wall St.) -6.82%

Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ENRIGHT PATRICK G	Director	Jun 23 '25	Buy	20.87	209,393	4,369,676	3,569,522	Jun 25 08:07 PM
ENRIGHT PATRICK G	Director	Jun 24 '25	Buy	22.35	40,607	907,635	3,596,593	Jun 25 08:07 PM
Fordyce Marshall	PRESIDENT AND CEO	Feb 21 '25	Sale	27.89	10,613	296,032	213,740	Feb 27 04:05 PM
Fordyce Marshall	PRESIDENT AND CEO	Feb 26 '25	Sale	27.65	9,075	250,882	204,665	Feb 27 04:05 PM
MARSHALL FORDYCE	Director	Feb 26 '25	Proposed Sale	27.10	9,075	245,932		Feb 26 04:21 PM
Fordyce Marshall	PRESIDENT AND CEO	Jan 08 '25	Option Exercise	2.90	17,500	50,694	153,578	Jan 10 04:06 PM
Fordyce Marshall	PRESIDENT AND CEO	Jan 08 '25	Sale	41.74	17,500	730,535	143,603	Jan 10 04:06 PM
MARSHALL FORDYCE	Director	Jan 08 '25	Proposed Sale	42.10	17,500	736,750		Jan 08 04:22 PM
Fordyce Marshall	PRESIDENT AND CEO	Dec 19 '24	Option Exercise	2.90	57,661	167,032	143,603	Dec 20 04:06 PM
Fordyce Marshall	PRESIDENT AND CEO	Dec 18 '24	Option Exercise	2.90	17,500	50,694	90,965	Dec 20 04:06 PM
Fordyce Marshall	PRESIDENT AND CEO	Dec 18 '24	Sale	43.07	17,500	753,680	85,942	Dec 20 04:06 PM
MARSHALL FORDYCE	Director	Dec 18 '24	Proposed Sale	43.91	17,500	768,425		Dec 18 04:24 PM
Fordyce Marshall	PRESIDENT AND CEO	Dec 11 '24	Option Exercise	2.90	17,500	50,694	100,867	Dec 13 04:07 PM
Fordyce Marshall	PRESIDENT AND CEO	Dec 11 '24	Sale	46.94	17,500	821,523	85,942	Dec 13 04:07 PM
MARSHALL FORDYCE	Director	Dec 11 '24	Proposed Sale	46.92	17,500	821,100		Dec 11 04:59 PM
Fordyce Marshall	PRESIDENT AND CEO	Nov 25 '24	Option Exercise	2.90	19,375	56,125	93,607	Nov 27 04:05 PM
Fordyce Marshall	PRESIDENT AND CEO	Nov 25 '24	Sale	47.98	19,375	929,560	85,942	Nov 27 04:05 PM
MARSHALL FORDYCE	Director	Nov 25 '24	Proposed Sale	48.31	19,375	936,006		Nov 25 04:40 PM
Fordyce Marshall	PRESIDENT AND CEO	Nov 13 '24	Option Exercise	2.90	30,625	88,714	98,160	Nov 15 04:05 PM
Fordyce Marshall	PRESIDENT AND CEO	Nov 13 '24	Sale	49.50	30,625	1,516,037	85,942	Nov 15 04:05 PM
MARSHALL FORDYCE	Director	Nov 13 '24	Proposed Sale	48.54	30,625	1,486,538		Nov 13 04:23 PM
SEIDENBERG BETH C	Director	Oct 28 '24	Sale	48.03	15,000	720,493	131,553	Oct 30 04:06 PM
BETH C SEIDENBERG	Director	Oct 28 '24	Proposed Sale	41.09	15,000	616,350		Oct 28 04:37 PM
Fordyce Marshall	PRESIDENT AND CEO	Oct 23 '24	Option Exercise	2.90	19,375	56,126	320,687	Oct 25 04:04 PM
Fordyce Marshall	PRESIDENT AND CEO	Oct 23 '24	Sale	40.39	19,375	782,610	307,972	Oct 25 04:04 PM
MARSHALL FORDYCE	Director	Oct 23 '24	Proposed Sale	40.71	19,375	788,756		Oct 23 04:16 PM
Fordyce Marshall	PRESIDENT AND CEO	Oct 09 '24	Option Exercise	2.90	15,625	45,262	320,245	Oct 11 04:05 PM
Fordyce Marshall	PRESIDENT AND CEO	Oct 09 '24	Sale	38.24	15,625	597,568	307,972	Oct 11 04:05 PM
MARSHALL FORDYCE	Director	Oct 09 '24	Proposed Sale	38.64	15,625	603,750		Oct 09 04:17 PM
Fordyce Marshall	PRESIDENT AND CEO	Sep 25 '24	Option Exercise	2.90	23,125	66,988	316,615	Sep 27 04:05 PM
Fordyce Marshall	PRESIDENT AND CEO	Sep 25 '24	Sale	46.05	23,125	1,064,809	307,972	Sep 27 04:05 PM
MARSHALL FORDYCE	Director	Sep 25 '24	Proposed Sale	46.71	7,500	350,325		Sep 25 04:21 PM
SEIDENBERG BETH C	Director	Sep 19 '24	Sale	42.31	13,823	584,793	146,553	Sep 20 04:45 PM
SEIDENBERG BETH C	Director	Sep 18 '24	Sale	42.00	1,476	61,992	4,012	Sep 20 04:45 PM
SEIDENBERG BETH C	Director	Sep 18 '24	Sale	42.01	1,177	49,448	160,376	Sep 20 04:45 PM
BETH C SEIDENBERG	Director	Sep 18 '24	Proposed Sale	40.02	15,000	600,300		Sep 18 04:38 PM
SAMUEL B SEIDENBERG IRREV TRUS	Director	Sep 18 '24	Proposed Sale	40.02	1,476	59,070		Sep 18 04:38 PM
Fordyce Marshall	PRESIDENT AND CEO	Sep 11 '24	Option Exercise	2.90	15,625	45,262	317,246	Sep 13 04:36 PM
Fordyce Marshall	PRESIDENT AND CEO	Sep 11 '24	Sale	37.50	15,625	585,934	307,972	Sep 13 04:36 PM
MARSHALL FORDYCE	Director	Sep 11 '24	Proposed Sale	37.55	31,250	1,173,438		Sep 11 04:19 PM
Fordyce Marshall	PRESIDENT AND CEO	Aug 28 '24	Option Exercise	2.90	15,625	45,262	337,592	Aug 30 04:04 PM
Fordyce Marshall	PRESIDENT AND CEO	Aug 28 '24	Sale	36.84	30,320	1,117,140	307,972	Aug 30 04:04 PM
MARSHALL FORDYCE	Director	Aug 28 '24	Proposed Sale	37.65	30,320	1,141,548		Aug 28 04:15 PM
Fordyce Marshall	PRESIDENT AND CEO	Aug 21 '24	Sale	39.76	14,471	575,425	322,667	Aug 23 05:40 PM
Fordyce Marshall	PRESIDENT AND CEO	Aug 14 '24	Option Exercise	2.90	15,625	45,262	352,763	Aug 16 04:31 PM
Fordyce Marshall	PRESIDENT AND CEO	Aug 14 '24	Sale	37.56	15,625	586,927	337,138	Aug 16 04:31 PM
MARSHALL FORDYCE	Director	Aug 14 '24	Proposed Sale	37.95	15,625	592,969		Aug 14 04:24 PM

Dollar change +0.00
Percentage change 0.12	%

Held by: VTI IWM VXF FESM IWO VTWO SCHA IWN IWC RSSL

Index	RUT	P/E	-	EPS (ttm)	-2.03	Insider Own	41.29%	Shs Outstand	35.85M	Perf Week	-2.39%
Market Cap	153.62M	Forward P/E	-	EPS next Y	-2.26	Insider Trans	0.02%	Shs Float	21.05M	Perf Month	8.48%
Enterprise Value	-156.59M	PEG	-	EPS next Q	-0.48	Inst Own	32.33%	Short Float	6.73%	Perf Quarter	7.39%
Income	-71.05M	P/S	105.94	EPS this Y	70.81%	Inst Trans	3.79%	Short Ratio	4.56	Perf Half Y	-30.21%
Sales	1.45M	P/B	0.49	EPS next Y	-16.59%	ROA	-27.15%	Short Interest	1.42M	Perf YTD	-25.99%
Book/sh	8.74	P/C	0.48	EPS next 5Y	28.50%	ROE	-30.20%	52W High	26.62 -83.90%	Perf Year	-
Cash/sh	8.94	P/FCF	-	EPS past 3/5Y	-30.62% -	ROIC	-22.43%	52W Low	2.88 48.78%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	88.22%	Volatility	5.30% 5.38%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-107.99	EPS Y/Y TTM	-	Oper. Margin	-5639.35%	ATR (14)	0.22	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	13.68	Sales Y/Y TTM	-	Profit Margin	-4896.28%	RSI (14)	51.08	Recom	3.50
Dividend Gr. 3/5Y	- -	Current Ratio	13.68	EPS Q/Q	5.16%	SMA20	-0.48%	Beta	-	Target Price	4.67
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	3.32%	Rel Volume	0.35	Prev Close	4.28
Employees	64	LT Debt/Eq	0.01	Earnings	May 06 AMC	SMA200	-52.37%	Avg Volume	311.03K	Price	4.28
IPO	Sep 26, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	31.95% -	Trades		Volume	6,581	Change	0.12%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-28-25	Initiated	William Blair	Mkt Perform
Dec-10-24	Downgrade	Morgan Stanley	Overweight → Underweight	$40 → $5
Dec-09-24	Downgrade	Jefferies	Buy → Hold	$42 → $7
Dec-09-24	Downgrade	Citigroup	Buy → Neutral	$45 → $7
Oct-21-24	Initiated	Morgan Stanley	Overweight	$40
Oct-21-24	Initiated	Jefferies	Buy	$42
Oct-21-24	Initiated	Citigroup	Buy	$45

Jun-21-25 06:00PM	BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions (GlobeNewswire)
Jun-17-25 09:00AM	BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank (GlobeNewswire)
Jun-03-25 09:00AM	BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates (GlobeNewswire)
May-30-25 09:05AM	BioAge Labs completes IND-enabling studies for BGE-102 (TipRanks)
May-29-25 11:18PM	BioAge Labs, Inc. (BIOA)'s BGE-102 Shows Potent Weight Loss, Plans IND Submission Mid-2025 (Insider Monkey)
09:00AM	Loading…
09:00AM	BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic (GlobeNewswire)
May-27-25 04:30PM	BioAge Labs to Present at Upcoming Investor Conferences (GlobeNewswire)
May-06-25 04:30PM	BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-21-25 01:02PM	BioAge Labs, Inc. (BIOA): A Bull Case Theory (Insider Monkey)
Mar-22-25 11:00AM	Investors To Focus On PCE Price Index Print As Cintas, Lululemon To Report Earnings (SeekingAlpha)
Mar-20-25 04:30PM	BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024 (GlobeNewswire)
Mar-17-25 01:54PM	BioArctic receives Orphan Drug Designation for exidavnemab the US (PR Newswire)
Mar-04-25 05:07AM	BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit - Hagens Berman (Newsfile)
Feb-20-25 04:30PM	BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference (GlobeNewswire)
10:36AM	BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit - Hagens Berman (Newsfile)
07:18AM	Loading…
Feb-16-25 07:18AM	BIOA COURT NEWS: BioAge Labs has been Sued for Securities Violations; Contact BFA Law by March 10 if You Lost Money (NASDAQ:BIOA) (GlobeNewswire)
Feb-14-25 05:45AM	Investors in BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA (PR Newswire) +5.97%
Feb-13-25 08:42AM	BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO- Hagens Berman (Newsfile)
Feb-07-25 05:45AM	BioAge Labs, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA (PR Newswire)
Jan-30-25 09:01AM	BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO- Hagens Berman (Newsfile)
Jan-29-25 05:39AM	BioAge drops obesity drug; Akero, 89bio cash in on MASH data (BioPharma Dive) -6.40%
Jan-28-25 07:27PM	Kessler Topaz Meltzer & Check, LLP Encourages BioAge Labs, Inc. Investors with Losses to Contact the Firm (PR Newswire)
09:00AM	BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs (GlobeNewswire)
Jan-24-25 05:45AM	Shareholders of BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA (PR Newswire)
Jan-22-25 03:00AM	After an obesity stumble, BioAge reconnects with its longevity pipeline (Pharma Voice)
Jan-21-25 05:45AM	Investors in BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA (PR Newswire)
Jan-18-25 03:07AM	BIOAGE LABS (BIOA) Investors are Notified the Company has been Sued and are Urged to Contact BFA Law by March 10 (Newsfile)
Jan-06-25 09:00PM	Bragar Eagel and Squire, P.C. Is Investigating Franklin, MediaAlpha, e.l.f. Beauty, and BioAge and Encourages Investors to Contact the Firm (GlobeNewswire) -7.39%
Jan-03-25 12:51PM	BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO- Hagens Berman (PR Newswire)
Jan-02-25 09:35AM	BioAge Labs, Inc. (BIOA) Loses -67.99% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
05:00AM	Loading…
Jan-01-25 05:00AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures - Hagens Berman (Newsfile)
Dec-27-24 11:32AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire) -6.46%
09:18AM	BioAge Labs, Inc. (BIOA): A Bull Case Theory (Insider Monkey)
Dec-26-24 07:23AM	Kirby McInerney LLP is Investigating Potential Shareholder Claims Against BioAge Labs, Inc. (BIOA) (Newsfile)
Dec-25-24 07:04AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures - Hagens Berman (Newsfile)
Dec-23-24 10:19AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire)
Dec-19-24 01:15PM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire) +20.23%
05:46AM	BioAge and Novartis seek drug targets for ageing-related diseases (Pharmaceutical Technology)
Dec-18-24 09:00AM	BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions (GlobeNewswire)
Dec-16-24 04:20PM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire)
03:00AM	3 closely watched drugs that failed in the clinic (Pharma Voice)
Dec-13-24 10:31AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures - Hagens Berman (Newsfile) -6.75%
Dec-12-24 06:34PM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire)
Dec-09-24 07:51PM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire) -76.85%
09:28AM	BioAge halts ongoing Phase II trial of obesity drug due to liver concerns (Clinical Trials Arena)
07:41AM	Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns (Benzinga)
Dec-07-24 06:34AM	BioAge shares tumble after decision to halt obesity drug study (BioPharma Dive)
Dec-06-24 04:35PM	BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity (GlobeNewswire) +9.36% -76.85%
Dec-05-24 04:30PM	BioAge Labs to Present at Goldman Sachs Year-Ahead Catalyst Clinic (GlobeNewswire)
Dec-04-24 04:47PM	Why BioAge Labs (BIOA) is the Best All-Time Low Stock to Buy Right Now? (Insider Monkey)
Nov-21-24 04:30PM	BioAge Labs to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-12-24 11:01PM	BioAge Labs Reports Strong Q3 2024 Achievements (TipRanks) -11.78%
Nov-07-24 04:30PM	BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -10.11% +7.61%
Nov-04-24 09:00AM	BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024 (GlobeNewswire)
Oct-24-24 09:00AM	BioAge Labs to Present at Jefferies London Healthcare Conference (GlobeNewswire)
Oct-21-24 10:53AM	Wall Street analysts initiate coverage of BioAge Labs (Investing.com) +8.26%
Oct-17-24 09:45AM	Prediction: These 2 Stocks Could Soar in 2025 (Motley Fool)
Oct-12-24 02:31PM	Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock (Motley Fool)
Oct-07-24 09:10PM	RA Capital Management, L.P. Acquires New Stake in Bioage Labs Inc (GuruFocus.com)
Oct-05-24 07:15AM	3 Reasons to Buy BioAge Labs Stock Hand Over Fist in October (Motley Fool)
Oct-03-24 09:05AM	This IPO Biotech Stock Could Be the Next Eli Lilly (Motley Fool) +5.73%
Oct-01-24 04:30PM	BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of the Concurrent Private Placement (GlobeNewswire)
Sep-26-24 04:08PM	BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rises On Upsized IPO (Investor's Business Daily)
02:36PM	A weight loss drug developer's stock soars after a $198 million IPO (Quartz)
08:25AM	BioAge Labs IPO: Stock price will be closely watched today as the obesity drug developer debuts on the Nasdaq (FastCompany)
Sep-25-24 08:00PM	BioAge Labs Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)
04:13PM	BioAge prices $198M IPO, validating pivot to obesity drug research (BioPharma Dive)
11:27AM	A weight loss drug maker is aiming for a big IPO (Quartz)
Jan-01-01 12:00AM	BioAge Labs, Inc. (BIOA)'s BGE-102 Shows Potent Weight Loss, Plans IND Submission Mid-2025 (Insider Monkey)

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. It offers Azelaprag, a potential oral therapeutic for obesity, followed by several earlier-stage metabolic programs. The company was founded by Kristen Fortney and Eric Morgen on April 1, 2015 and is headquartered in Richmond, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Barton Shane	Principal Accounting Officer	Sep 27 '24	Buy	18.00	2,632	47,376	2,632	Mar 10 04:10 PM
Pande Vijay Satyanand	Director	Oct 01 '24	Buy	19.73	126,793	2,501,626	1,026,793	Oct 03 07:19 PM
Pande Vijay Satyanand	Director	Oct 02 '24	Buy	19.73	67,096	1,323,804	1,093,889	Oct 03 07:19 PM
Pande Vijay Satyanand	Director	Oct 03 '24	Buy	19.90	25,306	503,589	1,119,195	Oct 03 07:19 PM
Cormorant Asset Management, LP	Former 10% Owner	Sep 27 '24	Buy	18.00	450,000	8,100,000	1,629,529	Oct 01 04:01 PM
Pande Vijay Satyanand	Director	Sep 27 '24	Buy	18.00	900,000	16,200,000	900,000	Sep 27 04:28 PM
ENRIGHT PATRICK G	Director	Sep 27 '24	Buy	18.00	400,000	7,200,000	1,710,589	Sep 27 04:26 PM
HEALY JAMES	Director	Sep 27 '24	Buy	18.00	666,665	11,999,970	2,227,124	Sep 27 04:22 PM

Open in Screener

ZBIO

Zenas Biopharma Inc

Jun 26 • 09:34AM ET

10.27

Dollar change +0.08
Percentage change 0.79	%

Healthcare • Biotechnology • USA • NASD

ZBIO Zenas Biopharma Inc daily Stock Chart

Held by: VTI IWM VXF VTWO IWO SCHA IWN FESM IWC SBIO

Index	RUT	P/E	-	EPS (ttm)	-3.98	Insider Own	75.62%	Shs Outstand	41.82M	Perf Week	10.31%
Market Cap	429.64M	Forward P/E	-	EPS next Y	-3.82	Insider Trans	0.11%	Shs Float	10.20M	Perf Month	-2.75%
Enterprise Value	118.49M	PEG	-	EPS next Q	-1.04	Inst Own	32.96%	Short Float	48.14%	Perf Quarter	27.42%
Income	-162.76M	P/S	28.64	EPS this Y	65.55%	Inst Trans	4.32%	Short Ratio	26.37	Perf Half Y	2.60%
Sales	15.00M	P/B	1.51	EPS next Y	6.69%	ROA	-85.03%	Short Interest	4.91M	Perf YTD	25.40%
Book/sh	6.80	P/C	1.38	EPS next 5Y	31.82%	ROE	-115.47%	52W High	26.25 -60.88%	Perf Year	-
Cash/sh	7.47	P/FCF	-	EPS past 3/5Y	-9.85% -	ROIC	-57.18%	52W Low	5.83 76.16%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	99.15%	Volatility	8.53% 10.34%	Perf 5Y	-
Dividend TTM	-	EV/Sales	7.90	EPS Y/Y TTM	-	Oper. Margin	-1157.59%	ATR (14)	0.96	Perf 10Y	-
Dividend Ex-Date	Dec 24, 2019	Quick Ratio	6.47	Sales Y/Y TTM	-	Profit Margin	-1085.07%	RSI (14)	51.01	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.47	EPS Q/Q	-10.71%	SMA20	0.15%	Beta	-	Target Price	32.14
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	1.10%	Rel Volume	0.57	Prev Close	10.19
Employees	130	LT Debt/Eq	0.00	Earnings	May 15 BMO	SMA200	-11.26%	Avg Volume	186.23K	Price	10.27
IPO	Sep 13, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	29.43% 499.99%	Trades		Volume	6,396	Change	0.79%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-20-25	Initiated	Wedbush	Outperform	$35
Feb-04-25	Initiated	Wolfe Research	Outperform	$19
Dec-16-24	Initiated	H.C. Wainwright	Buy	$30
Nov-05-24	Initiated	Rodman & Renshaw	Buy	$34
Oct-08-24	Initiated	Morgan Stanley	Overweight	$40
Oct-08-24	Initiated	Jefferies	Buy	$35
Oct-08-24	Initiated	Guggenheim	Buy	$45
Oct-08-24	Initiated	Citigroup	Buy	$27

Jun-20-25 04:15PM	Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-13-25 05:45AM	Zenas BioPharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ZBIO (PR Newswire) -8.75%
Jun-02-25 04:00AM	ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO (PR Newswire) +5.67%
May-29-25 07:05AM	Zenas BioPharma to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) +8.34%
May-28-25 09:31AM	ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO (PR Newswire) -12.59%
05:45AM	Loading…
May-16-25 05:45AM	Investors in Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO (PR Newswire) +7.49%
May-15-25 07:05AM	Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire) +12.21%
May-06-25 05:45AM	Zenas BioPharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ZBIO (PR Newswire) -19.71%
May-02-25 05:45AM	Shareholders of Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO (PR Newswire)
Apr-29-25 05:45AM	Zenas BioPharma, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO (PR Newswire) +12.56%
Apr-22-25 10:37AM	Cohen Milstein Calls on Zenas BioPharma (ZBIO) Investors to Act Following Significant Post-IPO Losses (GlobeNewswire)
Apr-21-25 12:33PM	Zenas Biopharma Investors Urged to Contact Cohen Milstein After Post-IPO Losses (GlobeNewswire) +9.30%
Apr-17-25 04:20PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.08%
Apr-07-25 03:08PM	Zenas: Differentiated B-Cell Targeting Drug With Q3 Of 2025 Catalyst (Seeking Alpha)
07:05AM	Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer (GlobeNewswire)
02:54PM	Loading…
Mar-20-25 02:54PM	Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress (Benzinga)
11:41AM	Zenas Bio rises as Wedbush launches with Outperform on lead asset (SeekingAlpha)
Mar-17-25 07:05AM	Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer (GlobeNewswire)
Feb-05-25 07:05AM	Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases (GlobeNewswire)
Jan-28-25 08:00AM	Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Dec-17-24 06:25AM	Zenas BioPharma initiated with a Buy at H.C. Wainwright (TipRanks) +8.10%
Dec-12-24 07:35AM	Zenas BioPharma price target lowered to $35 from $40 at Morgan Stanley (TipRanks)
Nov-12-24 07:10AM	Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
07:05AM	Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) (GlobeNewswire)
Nov-07-24 07:05AM	Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences (GlobeNewswire)
Oct-14-24 06:45AM	Opening Day: Another trio of biotech IPOs make Friday debut (TipRanks) +7.63%
Sep-19-24 04:15PM	Zenas BioPharma Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering (GlobeNewswire) +8.45%
Sep-13-24 04:09PM	Biotech IPO Shares Climb in Debuts After Deals Upsized (Bloomberg)
12:19AM	Bicara Leads Trio of US Biotech IPOs Raising $703 Million (Bloomberg)
Sep-12-24 10:37PM	Zenas BioPharma Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MOULDER LEON O JR	Chief Executive Officer	Feb 18 '25	Buy	6.67	25,000	166,750	266,155	Feb 19 04:01 PM
Xiao Ting	Director	Feb 07 '25	Buy	7.76	10,000	77,600	47,000	Feb 11 04:20 PM
MOULDER LEON O JR	Chief Executive Officer	Dec 04 '24	Buy	9.98	45,000	449,100	241,155	Dec 04 09:03 PM
MOULDER LEON O JR	Chief Executive Officer	Dec 03 '24	Buy	10.76	25,000	269,000	196,155	Dec 04 09:03 PM
MOULDER LEON O JR	Chief Executive Officer	Nov 18 '24	Buy	15.00	7,500	112,500	168,655	Nov 20 05:20 PM
MOULDER LEON O JR	Chief Executive Officer	Nov 19 '24	Buy	14.57	2,500	36,425	171,155	Nov 20 05:20 PM
MOULDER LEON O JR	Chief Executive Officer	Sep 18 '24	Buy	17.91	10,000	179,100	1,662,039	Sep 20 06:34 PM
MOULDER LEON O JR	Chief Executive Officer	Sep 20 '24	Buy	18.45	5,000	92,270	1,672,039	Sep 20 06:34 PM
MOULDER LEON O JR	Chief Executive Officer	Sep 19 '24	Buy	17.89	5,000	89,450	1,667,039	Sep 20 06:34 PM
Enavate Sciences GP, LLC	10% Owner	Sep 16 '24	Buy	17.00	882,353	15,000,001	3,761,359	Sep 18 04:15 PM
Lu Hongbo	Director	Sep 13 '24	Buy	17.00	58,823	999,991	58,823	Sep 17 07:52 PM
ENRIGHT PATRICK G	Director	Sep 16 '24	Buy	17.00	440,000	7,480,000	774,530	Sep 16 08:57 PM
Nunn Jason Raleigh	Director	Sep 16 '24	Buy	17.00	882,352	14,999,984	1,946,564	Sep 16 08:54 PM
Fairmount Funds Management LLC	Director	Sep 16 '24	Buy	17.00	300,000	5,100,000	1,604,891	Sep 16 08:54 PM
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	Sep 16 '24	Buy	17.00	2,235,294	37,999,998	1,946,564	Sep 16 08:51 PM

Dollar change 0.00
Percentage change 0.00	%

JAZZ Jazz Pharmaceuticals plc daily Stock Chart

Peers: VRTX REGN BIIB INCY GILD BMRN NBIX EXEL UTHR SAGE

| Held by: IJH VTI VB VXF VBR CALF MDY IJJ SPMD DFAT

Index	-	P/E	14.45	EPS (ttm)	7.42	Insider Own	4.71%	Shs Outstand	61.62M	Perf Week	-1.03%
Market Cap	6.48B	Forward P/E	4.97	EPS next Y	21.56	Insider Trans	2.45%	Shs Float	57.66M	Perf Month	-2.14%
Enterprise Value	9.33B	PEG	3.46	EPS next Q	-7.42	Inst Own	99.54%	Short Float	10.11%	Perf Quarter	-18.15%
Income	482.20M	P/S	1.59	EPS this Y	-76.35%	Inst Trans	0.95%	Short Ratio	4.98	Perf Half Y	-12.89%
Sales	4.06B	P/B	1.58	EPS next Y	336.26%	ROA	4.22%	Short Interest	5.83M	Perf YTD	-13.02%
Book/sh	67.75	P/C	2.52	EPS next 5Y	4.18%	ROE	12.25%	52W High	148.06 -27.65%	Perf Year	-2.47%
Cash/sh	42.50	P/FCF	4.28	EPS past 3/5Y	- -1.00%	ROIC	5.05%	52W Low	95.49 12.18%	Perf 3Y	-28.17%
Dividend Est.	-	EV/EBITDA	7.43	Sales past 3/5Y	9.56% 13.48%	Gross Margin	73.41%	Volatility	2.12% 2.46%	Perf 5Y	-6.01%
Dividend TTM	-	EV/Sales	2.30	EPS Y/Y TTM	49.58%	Oper. Margin	14.63%	ATR (14)	2.97	Perf 10Y	-40.71%
Dividend Ex-Date	-	Quick Ratio	2.97	Sales Y/Y TTM	5.76%	Profit Margin	11.86%	RSI (14)	45.33	Recom	1.17
Dividend Gr. 3/5Y	- -	Current Ratio	3.38	EPS Q/Q	-549.10%	SMA20	-1.73%	Beta	0.33	Target Price	182.80
Payout	0.00%	Debt/Eq	1.30	Sales Q/Q	-0.46%	SMA50	-1.09%	Rel Volume	0.15	Prev Close	107.12
Employees	2800	LT Debt/Eq	1.29	Earnings	May 06 AMC	SMA200	-9.36%	Avg Volume	1.17M	Price	107.12
IPO	Jun 01, 2007	Option/Short	Yes / Yes	EPS/Sales Surpr.	-63.93% -8.74%	Trades		Volume	10,655	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-07-25	Upgrade	UBS	Neutral → Buy	$145 → $179
Feb-26-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-13-25	Upgrade	Wells Fargo	Equal Weight → Overweight	$130 → $170
Dec-12-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$140 → $175
Jun-05-24	Initiated	Goldman	Buy	$169
Jan-03-24	Initiated	Robert W. Baird	Outperform	$160
Nov-27-23	Downgrade	UBS	Buy → Neutral	$170 → $135
Sep-29-23	Initiated	Raymond James	Mkt Perform
Jun-12-23	Resumed	Wells Fargo	Equal Weight	$184 → $140
Dec-09-22	Upgrade	Goldman	Neutral → Buy	$192 → $190
Jun-14-22	Initiated	UBS	Buy	$194
Apr-06-22	Downgrade	Goldman	Buy → Neutral	$202 → $196
Nov-19-21	Resumed	Goldman	Buy	$198
Oct-07-21	Resumed	Jefferies	Buy	$172
Oct-05-21	Initiated	Citigroup	Buy	$200
Sep-23-21	Initiated	Needham	Buy	$220
May-19-21	Resumed	JP Morgan	Overweight	$183 → $206
Apr-07-21	Resumed	RBC Capital Mkts	Outperform	$186
Feb-05-21	Reiterated	H.C. Wainwright	Buy	$195 → $207
Feb-03-21	Upgrade	Piper Sandler	Neutral → Overweight	$150 → $175

Show Previous Ratings

Jun-11-25 07:59PM	Jazz Pharmaceuticals Releases Unexpected Phase 4 Results Highlighting Xywav (Insider Monkey)
Jun-10-25 07:05AM	Zepzelca (lurbinectedin) and Atezolizumab (Tecentriq) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer (PR Newswire)
Jun-09-25 06:00PM	Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025 (PR Newswire)
Jun-05-25 11:30AM	Why Is Jazz (JAZZ) Up 7.9% Since Last Earnings Report? (Zacks)
Jun-02-25 04:05PM	Jazz Pharmaceuticals Announces Zepzelca (lurbinectedin) and Atezolizumab (Tecentriq) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer (PR Newswire)
12:35PM	Loading…
12:35PM	Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025 (PR Newswire)
May-29-25 07:30AM	Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025 (PR Newswire)
May-23-25 06:02AM	Insiders Pour Millions into These 3 Stocks Heres Why They Draw Plaudits Across the Board (TipRanks)
May-21-25 04:30PM	Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences (PR Newswire)
May-19-25 09:53AM	JAZZ Q1 Earnings Call: Revenue and Profit Miss, Product Pipeline Drives Outlook (StockStory)
May-13-25 09:16AM	Unlocking Jazz (JAZZ) International Revenues: Trends, Surprises, and Prospects (Zacks)
May-10-25 11:55AM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
May-09-25 08:51AM	Pharma Stock Roundup: NVO & JAZZ's Q1 Results, AZN's Pipeline Update (Zacks)
May-08-25 06:36PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research)
07:20AM	Cannabis Stock Tilray Brands Loses 19% in a Month: Time to Sell or Hold? (Zacks)
07:13PM	Loading…
May-07-25 07:13PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research) -8.75%
11:55AM	JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook (Zacks)
11:00AM	Appeals court reverses-in-part, vacates-in part ruling in Avadel-Jazz fight (TipRanks)
08:33AM	Jazz Pharmaceuticals (JAZZ): Among Billionaire Ray Dalio's Bridgewater's Stock Picks with Huge Upside Potential (Insider Monkey)
03:19AM	Jazz Pharmaceuticals PLC (JAZZ) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
May-06-25 11:06PM	Jazz Pharmaceuticals plc (JAZZ) Q1 2025 Earnings Call Transcript (Seeking Alpha) -5.94%
06:30PM	Here's What Key Metrics Tell Us About Jazz (JAZZ) Q1 Earnings (Zacks)
05:20PM	Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Lag Estimates (Zacks)
04:05PM	Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance (PR Newswire)
09:39AM	AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y (Zacks)
May-05-25 09:40AM	Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock (Zacks)
May-02-25 07:41PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research)
May-01-25 10:01AM	Illumina (ILMN) Earnings Expected to Grow: Should You Buy? (Zacks)
Apr-30-25 04:15PM	Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference (PR Newswire)
07:18AM	Buy, Sell or Hold JAZZ Stock? Key Tips Ahead of Q1 Earnings (Zacks)
09:30PM	Loading…
Apr-29-25 09:30PM	Franklin Convertible Securities Fund Q1 2025 Commentary (Seeking Alpha)
10:01AM	Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy? (Zacks)
08:14AM	3 Unconventional Cannabis Stocks to Watch in 2025 (Zacks)
Apr-28-25 05:33PM	Zymeworks: A Strong Buy With Newly-Approved Cancer Drug, Excellent Financials, And Expansive Pipeline (Seeking Alpha)
05:05AM	3 Reasons to Sell JAZZ and 1 Stock to Buy Instead (StockStory)
Apr-25-25 11:27AM	Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer (PR Newswire)
Apr-23-25 04:15PM	Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma (PR Newswire)
11:17AM	Buy 5 High ROE Stocks as Markets Break Tariff-Induced Losing Streak (Zacks)
Apr-22-25 04:15PM	Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025 (PR Newswire)
07:21AM	Cardiol Therapeutics Stock: Is Cannabis Potential Priced In? (Zacks)
Apr-21-25 04:05PM	Jazz Pharmaceuticals Completes Acquisition of Chimerix (PR Newswire)
09:22AM	Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria (Zacks)
07:36AM	JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play? (Zacks)
Apr-17-25 11:40AM	JAZZ vs. ARGX: Which Stock Is the Better Value Option? (Zacks)
09:40AM	Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term (Zacks)
07:49AM	Is Jazz Pharmaceuticals a Top Cannabis Investment for 2025? (Zacks)
05:06AM	Pharmaceuticals Stocks Q4 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers (StockStory)
Apr-16-25 11:47AM	Sanofi Advances Mid-to-Late-Stage Pipeline in Respiratory Indications (Zacks)
Apr-15-25 10:42AM	Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag (Zacks)
09:18AM	Ironwood Shares Tank on Regulatory Update for Apraglutide (Zacks)
Apr-14-25 09:51AM	Roche Gets Nod for Expanded Use of Columvi in Lymphoma in Europe (Zacks)
Apr-11-25 11:49AM	Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate (Zacks)
Apr-10-25 03:30PM	Harbor Mid Cap Value Fund Q4 2024 Commentary (Seeking Alpha) -7.33%
11:50AM	TG Therapeutics Shares Rise Almost 30% in 3 Months: Here's Why (Zacks)
11:05AM	TPST to Evaluate Strategic Options for Pipeline Studies, Stock Up (Zacks)
08:13AM	Jazz (JAZZ) Moves 7.1% Higher: Will This Strength Last? (Zacks)
06:20AM	Should John Hancock Multifactor Small Cap ETF (JHSC) Be on Your Investing Radar? (Zacks)
Apr-09-25 03:59PM	Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out (Seeking Alpha) +7.10%
08:45AM	JAZZ Pharmaceuticals Stock Trades Near 52-Week Low: Time to Buy or Sell? (Zacks)
Apr-08-25 06:56PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research)
Apr-07-25 10:53AM	AZN Gets EU Nod for Expanded Use of Two Separate Cancer Drugs (Zacks)
10:02AM	5 High ROE Stocks to Buy as Markets Face Tariff Bloodbath (Zacks)
06:20AM	Is John Hancock Multifactor Small Cap ETF (JHSC) a Strong ETF Right Now? (Zacks)
Apr-04-25 01:10PM	AMGN's Uplizna Gets FDA Nod for 2nd Rare Autoimmune Disease Indication (Zacks) -8.92%
Apr-03-25 11:27AM	SNY's Rilzabrutinib Gets FDA's Orphan Drug Tag for Two Rare Diseases (Zacks)
Apr-02-25 11:29AM	AXSM Stock Down on Top-Line Data From Depression Study on Solriamfetol (Zacks)
09:33AM	Alkermes Begins Idiopathic Hypersomnia Study on ALKS 2680 (Zacks)
Apr-01-25 10:55AM	VRTX Provides Mixed Updates for Type 1 Diabetes Pipeline Candidates (Zacks)
09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Mar-31-25 11:40AM	JAZZ or ARGX: Which Is the Better Value Stock Right Now? (Zacks)
Mar-29-25 04:15PM	Is Jazz Pharmaceuticals (JAZZ) the Best Mid Cap Biotech Stock to Buy? (Insider Monkey)
Mar-28-25 09:26AM	BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance (Zacks)
Mar-27-25 11:36AM	NTLA Genome-Editing Therapy Gets FDA's RMAT Tag for New Indication (Zacks)
11:30AM	Jazz (JAZZ) Down 9.2% Since Last Earnings Report: Can It Rebound? (Zacks)
07:30AM	Franklin Biotechnology Discovery Fund Q4 2024 Commentary (SeekingAlpha)
Mar-26-25 04:15PM	Jazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference (PR Newswire)
11:51AM	AXSM Stock Down Despite ADHD Study Meeting Primary Endpoint (Zacks)
Mar-25-25 05:39PM	Is Jazz Pharmaceuticals plc (JAZZ) a Promising Biotech Stock According to Wall Street Analysts (InsiderMonkey)
Mar-24-25 09:50AM	Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-Term (Zacks)
04:26AM	Zacks.com featured highlights include MPLX LP, Leidos, Jazz Pharmaceuticals, Fortinet and Pilgrim's Pride (Zacks)
Mar-22-25 04:09PM	TPB, ACB and JAZZ: Three Pot Stocks Flowering With Potential Upside (TipRanks)
Mar-21-25 12:04PM	5 High ROE Stocks to Buy as Markets Dip Despite Rate Cut Hopes (Zacks)
Mar-20-25 01:03PM	3 Promising Biotechs Trading Substantially Under Consensus Analyst Firm Price Targets (SeekingAlpha)
09:38AM	4 Top PEG Stocks Based on GARP Approach to Smart Investing (Zacks)
Mar-19-25 12:14PM	HRMY Down 10.8% in Six Months: How Should You Play the Stock? (Zacks)
09:55AM	Does Jazz (JAZZ) Have the Potential to Rally 38.94% as Wall Street Analysts Expect? (Zacks)
09:02AM	3 Value Stocks Skating on Thin Ice (StockStory)
07:30AM	Jazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Epidiolex (cannabidiol) at American Academy of Neurology Annual Meeting (PR Newswire)
Mar-17-25 11:21AM	Cash In On The Luck Of The Irish With 5 St. Patrick's Day Stocks Near Buy Points (Investor's Business Daily)
07:53AM	Five Irish Stocks Near Buy Points To Add Green To Your Portfolio On St. Patrick's Day (Investor's Business Daily)
Mar-14-25 09:40AM	Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock (Zacks)
Mar-12-25 06:00AM	Bull of the Day: Jazz Pharmaceuticals (JAZZ) (Zacks)
Mar-09-25 06:09PM	Why Chimerix, Inc. (CMRX) Soared Last Week (Insider Monkey)
Mar-05-25 01:03PM	Jazz Pharmaceuticals bids for Chimerix in $935m deal (Pharmaceutical Technology)
07:00AM	Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio (PR Newswire)
06:53AM	Jazz expands in oncology with $935M deal for Chimerix (BioPharma Dive)
Mar-04-25 08:07AM	3 Small-Cap Stocks Skating on Thin Ice (StockStory)
Mar-03-25 06:51PM	Jazz Pharmaceuticals plc (JAZZ): Among the Cash-Rich Mid Cap Stocks to Buy Now (Insider Monkey)
12:20PM	Earnings Estimates Moving Higher for Jazz (JAZZ): Time to Buy? (Zacks)
09:55AM	Wall Street Analysts See a 29.63% Upside in Jazz (JAZZ): Can the Stock Really Move This High? (Zacks)

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
COZADD BRUCE C	Chairman & CEO	Jun 03 '25	Sale	110.00	500	55,000	437,973	Jun 04 04:50 PM
COZADD BRUCE C	Chairman & CEO	Jun 02 '25	Sale	107.90	500	53,950	438,473	Jun 04 04:50 PM
COZADD BRUCE C	Officer	Jun 02 '25	Proposed Sale	108.95	1,000	108,950		Jun 02 05:03 PM
Mulligan Seamus	Director	May 09 '25	Buy	98.26	100,000	9,826,120	100,000	May 13 06:51 PM
Mulligan Seamus	Director	May 12 '25	Buy	103.00	1,621	166,962	101,621	May 13 06:51 PM
COZADD BRUCE C	Chairman & CEO	May 01 '25	Sale	116.35	1,000	116,350	439,307	May 05 07:00 PM
COZADD BRUCE C	Chairman & CEO	May 02 '25	Sale	120.00	500	60,000	438,807	May 05 07:00 PM
COZADD BRUCE C	Officer	May 01 '25	Proposed Sale	117.57	1,500	176,350		May 01 04:09 PM
COZADD BRUCE C	Chairman & CEO	Apr 01 '25	Sale	123.75	1,500	185,625	440,307	Apr 03 05:32 PM
COZADD BRUCE C	Officer	Apr 01 '25	Proposed Sale	125.31	2,000	250,625		Apr 01 04:32 PM
Iannone Robert	EVP, Global Head of R&D & CMO	Mar 10 '25	Sale	138.41	2,403	332,605	79,621	Mar 12 02:24 PM
Carr Patricia	SVP, Chief Accounting Officer	Mar 10 '25	Sale	137.81	1,140	157,103	7,012	Mar 11 06:17 PM
Iannone Robert	Officer	Mar 10 '25	Proposed Sale	145.00	1,767	256,215		Mar 10 06:01 PM
Carr Patricia	Officer	Mar 10 '25	Proposed Sale	137.81	1,140	157,103		Mar 10 05:36 PM
Iannone Robert	EVP, Global Head of R&D & CMO	Mar 07 '25	Sale	138.60	7,080	981,298	82,024	Mar 07 06:49 PM
ROBERT IANNONE	Officer	Mar 07 '25	Proposed Sale	138.73	5,466	758,305		Mar 07 05:14 PM
Iannone Robert	Officer	Mar 07 '25	Proposed Sale	142.26	4,017	571,476		Mar 07 05:04 PM
Henderson Mary Elizabeth	Officer	Mar 07 '25	Proposed Sale	139.00	1,295	180,005		Mar 07 03:15 PM
Carr Patricia	SVP, Chief Accounting Officer	Feb 27 '25	Option Exercise	113.77	4,813	547,562	12,737	Mar 03 07:21 PM
Carr Patricia	SVP, Chief Accounting Officer	Feb 27 '25	Sale	144.42	4,813	695,075	8,237	Mar 03 07:21 PM
Carr Patricia	SVP, Chief Accounting Officer	Feb 28 '25	Sale	143.29	773	110,767	9,485	Mar 03 07:21 PM
Patil Neena M	EVP & Chief Legal Officer	Feb 27 '25	Sale	144.87	3,800	550,506	33,318	Mar 03 07:18 PM
COZADD BRUCE C	Chairman & CEO	Mar 03 '25	Sale	144.25	6,500	937,625	464,058	Mar 03 07:13 PM
COZADD BRUCE C	Officer	Mar 03 '25	Proposed Sale	144.25	6,500	937,625		Mar 03 04:44 PM
Carr Patricia	Officer	Feb 28 '25	Proposed Sale	143.30	773	110,767		Feb 28 05:43 PM
Carr Patricia	Officer	Feb 27 '25	Proposed Sale	139.00	1,641	228,099		Feb 27 08:05 PM
Carr Patricia	Officer	Feb 27 '25	Proposed Sale	144.42	4,813	695,075		Feb 27 05:04 PM
Patil Neena M	Officer	Feb 27 '25	Proposed Sale	144.87	3,800	550,518		Feb 27 04:56 PM
COZADD BRUCE C	Chairman & CEO	Feb 03 '25	Sale	122.31	1,500	183,465	439,744	Feb 05 05:41 PM
COZADD BRUCE C	Officer	Feb 03 '25	Proposed Sale	122.31	1,500	183,465		Feb 03 05:04 PM
COZADD BRUCE C	Chairman & CEO	Jan 02 '25	Sale	123.43	1,500	185,145	425,525	Jan 06 04:22 PM
COZADD BRUCE C	Officer	Jan 02 '25	Proposed Sale	123.43	1,500	185,145		Jan 02 05:00 PM
COZADD BRUCE C	Chairman & CEO	Dec 02 '24	Sale	121.17	2,000	242,340	427,025	Dec 04 05:24 PM
Carr Patricia	SVP, Chief Accounting Officer	Dec 02 '24	Sale	122.49	53	6,492	6,596	Dec 04 05:20 PM
COZADD BRUCE C	Officer	Dec 02 '24	Proposed Sale	121.17	2,000	242,340		Dec 02 06:05 PM
Carr Patricia	Officer	Dec 02 '24	Proposed Sale	122.49	53	6,492		Dec 02 04:20 PM
Patil Neena M	EVP & Chief Legal Officer	Nov 08 '24	Sale	123.41	3,700	456,617	33,048	Nov 13 05:44 PM
Patil Neena M	Officer	Nov 08 '24	Proposed Sale	123.41	3,700	456,632		Nov 08 05:55 PM
COZADD BRUCE C	Chairman & CEO	Nov 01 '24	Sale	110.84	1,000	110,840	428,976	Nov 05 05:00 PM
COZADD BRUCE C	Officer	Nov 01 '24	Proposed Sale	110.84	1,000	110,840		Nov 01 03:19 PM
Henderson Mary Elizabeth	SVP, Technical Operations	Sep 06 '24	Sale	108.30	1,410	152,703	14,531	Sep 11 11:38 AM
Henderson Mary Elizabeth	Officer	Sep 06 '24	Proposed Sale	110.00	2,691	296,010		Sep 05 07:50 PM
Winningham Rick E	Director	Aug 06 '24	Proposed Sale	111.00	3,075	341,325		Aug 05 09:57 PM
Smith Mark Douglas	Director	Aug 06 '24	Proposed Sale	111.00	3,075	341,325		Aug 05 09:55 PM
RIEDEL NORBERT G	Director	Aug 06 '24	Proposed Sale	111.00	3,075	341,325		Aug 05 09:49 PM
ORiordan Anne	Director	Aug 06 '24	Proposed Sale	111.00	3,075	341,325		Aug 05 09:42 PM
O'Keefe Kenneth W	Director	Aug 06 '24	Proposed Sale	111.00	3,075	341,325		Aug 05 09:35 PM
McSharry Heather Ann	Director	Aug 06 '24	Proposed Sale	111.00	3,075	341,325		Aug 05 09:29 PM
Cook Jennifer E.	Director	Aug 06 '24	Proposed Sale	111.00	3,075	341,325		Aug 05 09:19 PM
Sohn Catherine A.	Director	Aug 05 '24	Proposed Sale	111.00	3,075	341,325		Aug 02 04:20 PM

VERA

Vera Therapeutics Inc

BIOA

BioAge Labs Inc

ZBIO

Zenas Biopharma Inc

JAZZ

Jazz Pharmaceuticals plc

Upgrade your FINVIZ experience